Limitations of Randomized Clinical Trials.
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
15 08 2020
15 08 2020
Historique:
received:
27
02
2020
revised:
27
04
2020
accepted:
05
05
2020
pubmed:
21
6
2020
medline:
11
11
2020
entrez:
21
6
2020
Statut:
ppublish
Résumé
Randomized clinical trials are essential for determining the efficacy of interventions, but have limitations. The types of limitations discussed in this review may be grouped in 11 categories including incorrect statistical inference, low internal or external validity, misinterpretation of the difference between frequentist and Bayesian statistical approaches, publication bias, that healthy persons with a given condition participate in clinical trials although they are not representative of the population as a whole, the rather short duration (3 to 5 years) that does not give correct estimates of the lifetime effects of the interventions or the legacy effect when participants who receive active therapy derive residual benefit after the end of the study when all participants receive active medication and the tension between the generalizability of the evidence versus the reliability of the findings of different types of clinical trials and the difficulty in applying the findings of randomized clinical trials to individual patients. These limitations are described and illustrated by examples and figures from the literature. In conclusion, this review will be useful to clinical trialists, clinical trial participants and regulatory agents.
Identifiants
pubmed: 32560898
pii: S0002-9149(20)30486-0
doi: 10.1016/j.amjcard.2020.05.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-115Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures All authors report no conflicts of interest.